Filtered By:
Specialty: Urology & Nephrology
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 1393 results found since Jan 2013.
Less Sodium, More Potassium, or Both: Population-wide Strategies to Prevent Hypertension
Am J Physiol Renal Physiol. 2023 Jun 1. doi: 10.1152/ajprenal.00007.2023. Online ahead of print.ABSTRACTHypertension is among the most prevalent medical conditions globally and a major contributor to chronic kidney disease, cardiovascular disease, and death. Prevention through non-pharmacologic, population-level interventions is critically needed to halt this worldwide epidemic. However, there are ongoing debates as to where public policy efforts should focus. Recently the Salt Substitute and Stroke Study demonstrated the efficacy of substituting table salt with potassium salt to reduce the risk of stroke, major cardiovasc...
Source: Am J Physiol Renal P... - June 1, 2023 Category: Urology & Nephrology Authors: Voravech Nissaisorakarn George Ormseth William Earle Martha Catalina Morales-Alvarez Swapnil Hiremath Stephen P Juraschek Source Type: research
Mechanistic and Clinical Comparison of the Erythropoietic Effects of SGLT2 Inhibitors and Prolyl Hydroxylase Inhibitors in Patients With Chronic Kidney Disease and Renal Anemia
Am J Nephrol. 2023 May 16. doi: 10.1159/000531084. Online ahead of print.ABSTRACTRenal anemia is treated with erythropoiesis-stimulating agents (ESA), even though epoietin alfa and darbepoietin increase the risk of cardiovascular death and thromboembolic events, including stroke. Hypoxia-inducible factor prolyl hydroxylase domain (HIF-PHD) inhibitors have been developed as an alternative to ESAs, producing comparable increases in hemoglobin. However, in advanced chronic kidney disease, HIF-PHD inhibitors can increase the risk of cardiovascular death, heart failure and thrombotic events to a greater extent than that with ES...
Source: American Journal of Nephrology - May 26, 2023 Category: Urology & Nephrology Authors: Milton Packer Source Type: research
Apixaban for stroke prevention in hemodialysis patients with non-valvular atrial fibrillation
Atrial fibrillation (AF) is a common arrhythmia among patients with kidney failure on maintenance hemodialysis (HD) and is associated with a high incidence of all-cause mortality and stroke in this population.1
Source: Kidney International - April 11, 2023 Category: Urology & Nephrology Authors: Thomas A. Mavrakanas Tags: nephrology digest Source Type: research
Apixaban for stroke prevention in hemodialysis patients with nonvalvular atrial fibrillation
Atrial fibrillation (AF) is a common arrhythmia among patients with kidney failure on maintenance hemodialysis (HD) and is associated with a high incidence of all-cause mortality and stroke in this population.1
Source: Kidney International - April 11, 2023 Category: Urology & Nephrology Authors: Thomas A. Mavrakanas Tags: Nephrology Digest Source Type: research
International Variability of Renal and Cardiovascular Outcomes and Mortality in Patients with Type 2 Diabetes Mellitus in Europe
Conclusion: Our findings show how the longitudinal outcome of patients with type 2 diabetes varies significantly across European countries even after accounting for the distribution of underlying risk factors.Kidney Blood Press Res 2023;48:165 –174
Source: Kidney and Blood Pressure Research - April 4, 2023 Category: Urology & Nephrology Source Type: research
The number of valvular insufficiency is a strong predictor of cardiovascular and all-cause mortality in hemodialysis patients
ConclusionsIn maintenance HD patients, the prevalence of VI is prominently high. The number of VI ≥ 2 is associated with emergency hospitalized for acute heart failure, cardiovascular and all-cause mortality. Combining age, number of VI ≥ 2, and albumin can predict cardiovascular and all-cause mortality.
Source: International Urology and Nephrology - April 3, 2023 Category: Urology & Nephrology Source Type: research
Predictors of quality of life in patients within the first year of commencing haemodialysis based on baseline data from the PIVOTAL trial and associations with the study outcomes
CONCLUSION: Quality of life was impaired in patients starting haemodialysis. A higher C-reactive protein level level was a consistent independent predictor of the majority of worse quality of life. Transferrin saturation ≤ 20% was associated with worse physical component score of quality of life. Baseline quality of life was predictive of all-cause mortality and the primary outcome measure.EUDRACT REGISTRATION NUMBER: 2013-002267-25.PMID:36995528 | PMC:PMC10061401 | DOI:10.1007/s40620-023-01571-6
Source: Journal of Nephrology - March 30, 2023 Category: Urology & Nephrology Authors: Sunil Bhandari Patrick Parfrey Claire White Stefan D Anker Kenneth Farrington Ian Ford Philip A Kalra John J V McMurray Michele Robertson Charles R V Tomson David C Wheeler Iain C Macdougall PIVOTAL Investigators, Committees Source Type: research
